GovBidAlerts
← All opportunities

Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula

Key dates

Posted
Sep 25, 2026
Response deadline
—
Archive date
Oct 10, 2026
Archive type
auto15

Classification

Notice type
Award Notice
Base type
Award Notice
Set-aside
—
Set-aside code
—
PSC
—

Issuing office

Department
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office
BARDA - ASPR / DAAPPO / BARDA DCMA
Office code
075.7505.75A501
Organization type
OFFICE
Office address
WASHINGTON, DC, 20515, USA

Place of performance

Street
—
Street 2
—
City
Jersey City
State
New Jersey
Zip
07302
Country
UNITED STATES

Contacts

Description

The full description is temporarily unavailable (SAM.gov rate limit) and will appear here shortly. View it now on SAM.gov ↗

Award

Number
75A50126C00007
Amount
$213,943,726.00
Date
Sep 25, 2026
Awardee
Scynexis, Inc. Jersey City NJ 07302 USA
UEI
—
Awardee address
Jersey City, New Jersey, 07302, UNITED STATES

Other notices in this solicitation

Similar open contracts

Metadata

Notice ID
5d2b1c5f6d094d72ad9916f20fc33ed3
Full path
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Office code
075.7505.75A501
Ingested
Sep 26, 2026
Updated
Sep 29, 2026